v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ (DEFICIT)/EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated deficit
Accumulated other Comprehensive Income (loss)
Statutory reserves
Beginning balance (in shares) at Dec. 31, 2020   99,028,297        
Beginning balance at Dec. 31, 2020 $ (384,602) $ 6 $ 0 $ (397,996) $ 7,356 $ 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (159,844)     (159,844)    
Accretion for Series C1 Preferred (2,257)     (2,257)    
Accretion for Series C2 Preferred (5,132)     (5,132)    
Accretion for Series D1 Preferred (10,708)     (10,708)    
Accretion for redeemable noncontrolling interests (5,841)     (5,841)    
Accretion for the exiting noncontrolling interests (3,682)     (3,682)    
Issuance of common stock upon the reverse recapitalization, net of issuance costs of $42.8 million (in shares)   191,254,950        
Issuance of common stock upon the reverse recapitalization, net of issuance costs of $42.8 million 1,241,671 $ 23 1,241,648      
Share-based compensation (in shares)   8,551,647        
Share-based compensation 49,552 $ 1 49,551      
Foreign currency translation adjustments (2,373)       (2,373)  
Ending balance (in shares) at Sep. 30, 2021   298,834,894        
Ending balance at Sep. 30, 2021 716,784 $ 30 1,291,199 (585,460) 4,983 6,032
Beginning balance (in shares) at Jun. 30, 2021   99,028,297        
Beginning balance at Jun. 30, 2021 (451,306) $ 6 0 (465,457) 8,113 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (116,476)     (116,476)    
Accretion for Series C1 Preferred (251)     (251)    
Accretion for Series C2 Preferred (570)     (570)    
Accretion for Series D1 Preferred (1,190)     (1,190)    
Accretion for redeemable noncontrolling interests (658)     (658)    
Accretion for the exiting noncontrolling interests (858)     (858)    
Issuance of common stock upon the reverse recapitalization, net of issuance costs of $42.8 million (in shares)   191,254,950        
Issuance of common stock upon the reverse recapitalization, net of issuance costs of $42.8 million 1,241,671 $ 23 1,241,648      
Share-based compensation (in shares)   8,551,647        
Share-based compensation 49,552 $ 1 49,551      
Foreign currency translation adjustments (3,130)       (3,130)  
Ending balance (in shares) at Sep. 30, 2021   298,834,894        
Ending balance at Sep. 30, 2021 716,784 $ 30 1,291,199 (585,460) 4,983 6,032
Beginning balance (in shares) at Dec. 31, 2021   298,843,016        
Beginning balance at Dec. 31, 2021 686,698 $ 30 1,306,034 (632,099) 6,701 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ (124,502)     (124,502)    
Accounting standards update Accounting Standards Update 2016-13 [Member]          
Issuance of common stock in connection with vesting of share-based awards (in shares)   8,761,551        
Issuance of common stock in connection with vesting of share-based awards $ 0 $ 1 (1)      
Share-based compensation 92,138   92,138      
Foreign currency translation adjustments (37,612)       (37,612)  
Ending balance (in shares) at Sep. 30, 2022   307,604,567        
Ending balance at Sep. 30, 2022 615,856 $ 31 1,398,171 (757,467) (30,911) 6,032
Beginning balance (in shares) at Jun. 30, 2022   300,859,266        
Beginning balance at Jun. 30, 2022 654,004 $ 30 1,378,774 (720,923) (9,909) 6,032
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (36,544)     (36,544)    
Issuance of common stock in connection with vesting of share-based awards (in shares)   6,745,301        
Issuance of common stock in connection with vesting of share-based awards 0 $ 1 (1)      
Share-based compensation 19,398   19,398      
Foreign currency translation adjustments (21,002)       (21,002)  
Ending balance (in shares) at Sep. 30, 2022   307,604,567        
Ending balance at Sep. 30, 2022 $ 615,856 $ 31 $ 1,398,171 $ (757,467) $ (30,911) $ 6,032